Login to Your Account

BiDil Shadow Looms

CombinatoRx Phase II Bounty Tests Generic-Pairing's Curse

By Randy Osborne

Monday, June 22, 2009
CombinatoRx's "Sophie's choice" situation with a pair of Phase II drugs may get resolved not by the cash-lean company but by a partner, and the question could depend on how spooked are investors by the calamity that ensued from NitroMed's attempt to grab market share with a drug that pairs two generics.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription